Immunology Market Size (2022 – 2030)

As per our research report, the global Immunology Market size was USD 10121 million in 2022 and is estimated to grow to USD 14901 million by 2030. This market is witnessing a healthy CAGR of 8.85% from 2023 - 2030. Innovations and developments in the immunological technologies focused on exploring the application, The surge in the prevalence rate of the different types of cancer and rheumatoid cancer, rising government initiatives, and increasing funding from the various government and non-government organizations are majorly driving the growth of the industry.

The immune system is a set of structures and processes within the body that protect against foreign bodies and potentially harmful diseases. It identifies various threats such as bacteria, viruses, and parasites and distinguishes them from healthy body tissues.

When the immune system weakens and loses its ability to detect and destroy abnormal cells or attacks the body and damages its tissues, this leads to diseases such as cancer and autoimmune diseases. Immunotherapy is a process that includes treatment by inducing, strengthening, or suppressing the immune system to fight disease.

According to the American Association of Autoimmune Diseases, autoimmune diseases affect 50 million Americans. There are 80 types of autoimmune diseases, of which the most common are rheumatoid arthritis, systemic lupus erythematosus (lupus), juvenile rheumatoid arthritis, enterocolitis, psoriatic arthritis, and affect the muscles. various organs of the body such as joints, muscles, skin, red blood cells, blood vessels, connective tissue, and endocrine glands.

Immunopharmaceuticals are becoming the choice of many oncologists because they provide long-term effects by activating the immune system to identify cancer cells and destroy them through a natural process of coagulation. while improving the quality of survival. Several FDA-approved cancer vaccines, bacille CalmetteGuérin (BCG), and SipuleucelT promote the growth of the immunotherapy market. Immunology is a branch of medicine and biology that studies the immune system. The immune system protects us against infection in many different ways. Diseases such as autoimmune, allergies, and cancer can occur when a person's immune system does not work properly. Autoimmune diseases occur when the immune system attacks the body it is supposed to protect. People with autoimmune diseases have defects that prevent their immune systems from distinguishing "self" from "selfless" or "foreign" molecules. Immunology offers a variety of laboratory tests to detect autoimmune diseases.

MARKET DRIVERS

Recent product approvals by regulatory agencies is estimated to drive the growth of the market

New drug approvals and trends in clinical improvement bode well for the global immunology industry. For example, the Food and Drug Administration (FDA) authorized AbbVie to use "SKYRIZI" in 2022. The drug was developed to treat moderate to severe plaque psoriasis. This medication is designed to treat adults with psoriasis who have been prescribed or are being treated.

An increase in the Number of Various diseases such as cancer and others is also driving the growth of the market

The increase in the prevalence of various types of cancer and rheumatoid cancer, increase in government initiatives, and increase in funding from various governmental and non-governmental organizations are driving the market of immunosuppressive drugs. Translate. Patients with a poor prognosis are estimated to stimulate the development of immunology. Evidence from trials shows that after preparing the immune system to fight cancer, the effects of the drug last even after the tumor has shrunk.

MARKET RESTRAINTS

High Cost Associated with the treatment is restraining the growth of the market

The high cost of immunology drugs, side effects associated with these drugs and lack of awareness are the key factors that may hinder the growth of the global immunology market. For example, according to data reported by the New York Times from SSR Health, a research firm, the price of Humira (a prescription injectable drug used to treat rheumatoid arthritis and other conditions) has increased from approximately $19,000 USD per year (in 2012) over US$38,000 per year (2022) per patient.

Market Segmentation

This research report on the Immunology market has been segmented and sub-segmented based on the following categories:

Immunology Market – By Drug Type:

• Monoclonal Antibodies
• Fusion Proteins
• Immunosuppressants
• Polyclonal Antibodies

On the basis of drug classes, the global immunology market is segmented into monoclonal antibodies, fusion proteins, immunosuppressants, and polyclonal antibodies. Monoclonal antibodies are antibodies produced by identical immune cells, all of which are copies of a parent cell. Monoclonal antibodies can have monovalent affinity, where they bind to the same epitope. Monoclonal antibodies are used to enhance and suppress the immune response in various pathologies such as cancer, cardiovascular and cerebrovascular which increase the demand for monoclonal antibodies. Fusion proteins are created by joining two or more genes that initially code for separate proteins.

Naturally, fusion proteins are commonly found in cancer cells, where they can function as oncoproteins. Factors such as those used for AIDS clearance, and the increasing application of fusion proteins, which are more stable and soluble in host cells compared to native proteins, drive the need for fusion proteins in the forecast period. Immunosuppressants are a group of drugs that suppress the strength of the body's immune system. Some of these drugs are used to make the body able to reject a transplanted organ, such as a liver, heart, or kidney. These drugs are called antirejection drugs.

The main factors driving the need for immunosuppressive drugs are complications associated with organ transplantation, such as the recipient's body recognizing the transplanted organ or tissue as foreign and causing a transfusion reaction. Polyclonal antibodies are antibodies produced by different lines of B cells in the body. It is a collection of immunoglobulin molecules that react against a specific antigen, each defining a different epitope. Тhе polyclonal аntіbоdу segment іѕ growing оwіng tо thе fаvоrаblе есоnоmіс еnvіrоnmеnt, rоbuѕt grоwth of thе рhаrmасеutісаlѕ іnduѕtrу, inсrеаѕе rеѕеаrсh асtіvіtіеѕ іn lіfе ѕсіеnсеѕ іnduѕtrіеѕ, and grоwіng рrоtеоmісѕ аnd gеnоmісѕ rеѕеаrсh.

Immunology Market - By Disease Indications:

• Rheumatoid Arthritis

• Psoriatic Arthritis
• Ankylosing Spondylitis
• Transplant Rejection Prophylaxis

In terms of disease indications, the global immunology market is segmented into rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and transplant rejection prophylaxis. Rheumatoid arthritis is an autoimmune disease caused by the immune system attacking the body's healthy tissues. The immune system normally produces antibodies that attack bacteria and viruses, helping to fight infections. Rheumatoid factor blood tests help diagnose rheumatoid arthritis. Rheumatoid factor is an antibody that can be detected in the blood of about 80% of adults with rheumatoid arthritis. Rheumatoid factor testing is used by healthcare professionals to help diagnose rheumatoid arthritis. The prevalence of rheumatoid arthritis, a growing aging population, and orthopedic disorders are estimated to drive demand for rheumatoid arthritis testing kits.

Psoriatic arthritis is a form of arthritis that affects people with psoriasis, a condition characterized by red patches of skin with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but joint problems can sometimes begin before the patches appear. Blood tests may be done to check for signs of inflammation. These include C-reactive protein and rheumatoid factor. People with psoriatic arthritis are nearly RF negative. There is a significant paradigm shift in the treatment of psoriatic arthritis, due to the targeted effects of biologics, the emergence of biological lenses, and consumer demand for effective drugs. on cost with improved safety. Ankylosing spondylitis is an inflammatory disease that over time can cause some of the small bones in the spine to fuse together. This fusion makes the spine less flexible and can lead to a forward-curved posture. The HLAB27 test is primarily indicated to help support or confirm a suspected diagnosis of ankylosing spondylitis.

Demand for ankylosing spondylitis test kits is estimated to increase during the forecast period due to increased spending on research and development, an increasing number of people seeking treatment, and unmet demand. current treatment on appropriate medications. Individuals undergoing organ transplantation should be maintained long-term on an immunosuppressive regimen to prevent rejection to help ensure graft survival. Organ rejection prevention is associated with the prevention of tissue/transplant rejection in patients who have undergone an organ transplant procedure. Increased risk factors for organ damage such as trauma, an increase in diseases such as diabetes, high blood pressure, and stroke are driving large numbers of patients to organ transplants, and the rate of organ donation by recipients Increased awareness is a major factor driving the need to prevent transplant rejection.

Immunology Market - By Region:

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

Geographically North America holds the largest share of the global immune pharmaceuticals market due to better reimbursement policies, high potential to invest large sums in immunotherapy drug development, and technological advancements.

Europe is the second-largest region in terms of value due to easy access to immunotherapy and the high affordability of treatment. Increased awareness, growing economy, increase in government initiatives and large patient population in Asia-Pacific regions also indicate higher growth of the drug market immunity In the global immunology market.

Immunology Market Share by company

Companies like AbbVie Inc., Janssen Global Services, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and Allergan plc. and others are playing a pivotal role in the market.

Recently Johnson & Johnson and its Janssen Pharmaceutical Companies plan to launch or file for regulatory approval more than 10 new products with “blockbuster potential” over the next by the end of 2022. With a growing core business of differentiated medicines and a strong line-up of innovative products estimated to launch or file over the next five years, Johnson and Johnson are leading the industry in advancing the health of patients around the world.

Suppliers invest in research and development to develop technologically advanced systems that give them a competitive advantage over other providers and provide an economic benefit to the industry. The industry is estimated to see several mergers and acquisitions over the next few years. Companies are taking proactive steps to gain market share and provide a diversified product portfolio.

NOTABLE HAPPENINGS IN THE IMMUNOLOGY MARKET IN THE RECENT PAST:

Agreement - In April 2022, ImaginAb and [Yantai] Dongcheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community.

Collaboration - In April 2022, AbbVie, Inc. announced the acquisition of Allergan Plc with an aim to expand its presence and strengthen its position in the pharmaceuticals sector across the globe.

COVID-19 impact on Immunology Market

Since the outbreak of the COVID19 virus in December 2022, the disease has spread to more than 100 countries around the world and the World Health Organization has declared it a public health emergency in 2022. According to the World Health Organization's Weekly Epidemiology of Coronavirus Disease (COVID19) Update, the number of COVID19 cases reported worldwide as of August 2, 2022, is approximately 198,234,951 confirmed cases with approximately 4,227,359 deaths. The Coronavirus or COVID19 outbreak started in Wuhan, China, and has spread across continents affecting many different industries around the world.

The negative effects of the global pandemic, COVID19, have been felt in a number of economies that are facing unprecedented losses, this is due to the embargo of government agencies, thus Several industries have been suspended with restricted activity activities. However, a collective effort by government and industry could possibly put the economy on track and help industrial activity resume. New drug approvals and trends in clinical improvement bode well for the global immunology industry. For example, the Food and Drug Administration (FDA) authorized AbbVie to use "SKYRIZI" in 2022. The drug was developed to treat moderate to severe plaque psoriasis. This medication is designed to treat adults with psoriasis who have been prescribed or are being treated.